Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 29,614 shares, a growth of 72.2% from the December 31st total of 17,195 shares. Approximately 1.8% of the company’s stock are short sold. Based on an average daily trading volume, of 20,559 shares, the days-to-cover ratio is presently 1.4 days. Based on an average daily trading volume, of 20,559 shares, the days-to-cover ratio is presently 1.4 days. Approximately 1.8% of the company’s stock are short sold.

Catheter Precision Stock Down 6.7%

NYSEAMERICAN VTAK traded down $0.14 during trading hours on Friday, hitting $1.94. 10,773 shares of the company’s stock traded hands, compared to its average volume of 22,029. The business’s fifty day moving average price is $2.11 and its two-hundred day moving average price is $2.55. Catheter Precision has a 52 week low of $1.49 and a 52 week high of $15.68. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.46 and a current ratio of 0.46.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($26.60) by $24.90. Catheter Precision had a negative net margin of 2,333.29% and a negative return on equity of 208.54%. The firm had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $1.20 million. On average, research analysts expect that Catheter Precision will post -8.9 earnings per share for the current fiscal year.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.